foxo4-dri senolytic peptide human trial 2024 2025 Frontiers Senolytics: charting a new course
Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7




